Baseline patient and disease characteristics by subsequent mSASSS change at Week 104 among patients with mSASSS and VEGF data through Week 104. Values are % (n/N) or median (mean ± SD) unless otherwise specified.
| Baseline Characteristics | mSASSS Change at Week 104 | p* | |
|---|---|---|---|
| ≥ 2 | < 2 | ||
| Patients, n | 23 | 86 | |
| Male | 78.3 (18/23) | 66.3 (57/86) | 0.2706 |
| Age, yrs | 41.0 (44.0 ± 13.98) | 40.0 (40.6 ± 11.69) | 0.2637 |
| Duration of AS diagnosis, yrs | 9.6 (11.9 ± 10.66) | 5.3 (9.0 ± 9.50) | 0.1957 |
| HLA-B27–positive | 82.6 (19/23) | 79.1 (68/86) | 0.7072 |
| CRP, mg/dl | 2.2 (2.4 ± 1.84) | 1.0 (1.5 ± 1.51) | 0.0048 |
| PtGA of disease, 0–10 | 7.5 (7.5 ± 1.71) | 7.2 (7.0 ± 1.71) | 0.1885 |
| BASDAI score, 0–10 | 7.0 (7.0 ± 1.50) | 6.7 (6.8 ± 1.42) | 0.5167 |
| BASFI score, 0–10 | 6.9 (6.8 ± 1.94) | 5.9 (5.5 ± 2.16)** | 0.0067 |
| BASMI score, 0–10 | 5.0 (5.5 ± 1.78) | 3.0 (3.3 ± 2.01) | < 0.0001 |
| mSASSS | 15.3 (22.1 ± 16.39) | 2.6 (10.7 ± 18.09) | < 0.0001 |
↵* P value for comparison of patients with mSASSS change from baseline to Week 104 ≥ 2 vs < 2.
↵** n = 85. mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score; VEGF: vascular endothelial growth factor; AS: ankylosing spondylitis; CRP: C-reactive protein; PtGA: patient’s global assessment; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index.